[go: up one dir, main page]

WO1999007842A1 - Materiel et methodes de selection de liants de ligands presentant un phage - Google Patents

Materiel et methodes de selection de liants de ligands presentant un phage Download PDF

Info

Publication number
WO1999007842A1
WO1999007842A1 PCT/GB1998/002371 GB9802371W WO9907842A1 WO 1999007842 A1 WO1999007842 A1 WO 1999007842A1 GB 9802371 W GB9802371 W GB 9802371W WO 9907842 A1 WO9907842 A1 WO 9907842A1
Authority
WO
WIPO (PCT)
Prior art keywords
phage
bacteria
ligand
infection
mediating
Prior art date
Application number
PCT/GB1998/002371
Other languages
English (en)
Inventor
Roland Carlsson
Lena Danielsson
Original Assignee
Bioinvent International Ab
Kiddle, Simon, John
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent International Ab, Kiddle, Simon, John filed Critical Bioinvent International Ab
Priority to AU86404/98A priority Critical patent/AU8640498A/en
Publication of WO1999007842A1 publication Critical patent/WO1999007842A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Definitions

  • the present invention relates to materials and methods for selecting ligand binders displayed on the surface of phage particles that bind to a target ligand, and more particularly to a method for selecting phages displaying ligand binders using the interaction between the ligand binder and an infection mediating complex comprising a target ligand and a component capable of making the phage infective towards bacteria having a certain type of infection mediating structure.
  • the display of peptides and polypeptides on the surface of bacteriophage (phage) fused to one of the coat proteins is a powerful technique for the selection of specific ligands.
  • the display of small peptides as fusions with phage coat proteins was first described by Smith in 1985 and has since been used in a range of different applications.
  • phage display technology The principles behind phage display technology are as follows. Nucleic acid encoding the peptides or polypeptides for display is cloned into a phage or a phagemid vector (i.e. a vector comprising origins of replication derived from a phage and a plasmid) that can be packaged as single stranded nucleic acid in a bacteriophage coat.
  • a "helper phage" is used to supply the functions of replication and packaging of the phagemid nucleic acid.
  • the cloned nucleic acid is expressed fused to the coat-anchoring part of one of the phage coat proteins (typically the p3 or p8 coat proteins in the case of filamentous phage) , it is displayed on the surface of the phage, thus linking phenotype to genotype.
  • the resulting phage will express both wild type coat protein (encoded by the helper phage) and modified coat protein (encoded by the phagemid) when a phagemid vector is used, and only modified coat protein when a phage vector is used. Selection based on phenotype will give the genotype that can be sequenced, multiplied and transferred to expression systems.
  • a major problem with phage display work aiming at isolating binding proteins with improved affinity or specificity for a target ligand resides in the selection of phage expressing the protein fragments of the desired quality.
  • a widely used method for selection is "panning" , in which phage stocks displaying ligands are exposed to solid-phase coupled target molecules.
  • panning often results in high backgrounds due to the binding of non-specific phage.
  • SAP Selection and Amplification of Phages; WO 95/16027) and SIP (Selectively-Infective Phage; EP 0614989A) employ selection based on the amplification of phages in which the displayed ligand specifically binds to a ligand binder.
  • this is achieved by using non- infectious phage and connecting the ligand binder of interest to the N-terminal part of p3.
  • the ligand binder specifically binds to the displayed ligand the otherwise non-infective ligand-expressing phage is provided with the parts of p3 needed for infection.
  • the selection can thus be based on kinetic parameters (Duenas et al .
  • Phage carrying high affinity ligands i.e. with high equilibrium constants for association (which in turn depends on the kinetic rate constants) can thus be selected for by varying the concentration of ligand.
  • the present invention provides materials and methods for selecting phage displaying specific ligand binders, e.g. antibodies or antibody fragments.
  • phage displaying specific ligand binders e.g. antibodies or antibody fragments.
  • Large antibody libraries constructed using conventional technology with phage or phagemid vectors can be used in these methods.
  • this method does not rely upon creation of phage particles that have been engineered to be non-infectious, allowing the use of ordinary phages and helper phages. Instead, phage retaining their wild-type ability to infect bacteria via one type of infection mediating structure (e.g. F-pili) are engineered to display ligand binders so that binding with an infection mediating complex comprising a ligand which specifically binds to the ligand binder causes the phage to become infectious towards bacteria having a different infection mediating structure (e.g. N-pili) to which the phage were initially substantially non-infectious .
  • F-pili infection mediating structure
  • the infectivity of phages for bacteria is controlled by selective use of host cells and ligands combined with infection mediating proteins or polypeptides that make phage infective towards a given type of bacteria on binding of the infection mediating complex to the displayed ligand binder.
  • the present invention can therefore be used in combination with conventional libraries.
  • the present invention provides a method for selecting phages displaying ligand binders that specifically bind to a target ligand, the method comprising:
  • the "infection mediating structure” is a structure of the bacteria which phage can use to infect the bacteria via interaction with phage coat proteins.
  • infections mediating structures in filamentous phage include F-pili which interact with Ff p3 or minor coat protein, and N-pili or I-pili which interact with IKe p3 protein.
  • Embodiments of the invention employing different types of pili are described in more detail below.
  • other types of phage can also be used in the invention, such as ⁇ phage, in which case the lamB gene product of the bacteria could be used as the infection mediating structure (see Bradley et al . , 1980) .
  • a library of ligand binders contained in, e.g. M13 filamentous phages will not significantly infect bacteria expressing N-pili, but which are devoid of F-pili.
  • Phage particles displaying ligand binders such as antibodies specific for a certain antigen, can be given the ability to infect N-pili carrying bacteria if they bind to an infection mediating complex comprising the N-terminal part of p3 from N-pili restricted phage like IKe (Khatoon et al . , 1972) and the antigen.
  • the antigen may be linked to the N-terminal part preferably comprising the glycine rich linker region of IKe p3
  • phage normally restricted to infect N-pili carrying bacteria can be exposed to antigen linked to p3 from M13 of Ff phages to allow this phage to infect F-pili expressing bacteria. It may also be possible to manipulate the infectivity of phage, e.g. F-pili restricted phage, to become N-pili restricted by substituting the N-terminal region (s) of p3 from such phages to an N-terminal region from F-pili restricted phage .
  • plasmids containing the genetic information for the ligand binder can be prepared from the selectively infected bacteria, introduced into F-pili (or N-pili) carrying bacteria and packaged into phage particles by use of a helper phage.
  • a M13 helper phage could be used to infect F-pili carrying bacteria, leading to the production of phage particles capable of infecting F-pili bacteria, but substantially incapable of infecting N-pili carrying bacteria.
  • the plasmids introduced into the F-pili (or N-pili) carrying bacteria would carry all the genetic information for formation of phage particles and there would be no need for a helper phage.
  • the phage particles thus produced can then be subjected to an additional round of selection using the infection mediating complex comprising the antigenic epitope and the N-terminal part of N-pili restricted p3 and N-pili carrying bacteria.
  • phage particles restricted on one type of pili might be changed to be restricted on another type of pili. It has been demonstrated that M13 phage with the ability to infect bacteria expressing F- pili can be given the additional ability to infect bacteria expressing N-pili. This was achieved through transplantation of the N-terminal part of p3 from an N- pili restricted phage (IKe) to p3 of M13 (Marzari et al . , 1997) . The resulting chimeric p3 contained domains that bound both types of pili. Alternatively, the removal of the F-pili binding domain of, e.g.
  • the present invention can be started using either N or F-pili bacteria, in conjunction with their respective phages and fusion proteins.
  • steps (a) to (d) can be used, and optionally the phage particles displaying ligand binders that are formed as a result of the method can be subjected to a second round of selection, starting the process again at step (b) .
  • the method can additionally comprise one or more of the following steps:
  • step (g) using the nucleic acid recovered in step (f) to repeat steps (a) to (d) .
  • the present invention includes the step of constructing the library of phage particles displaying the ligand binders, the method comprising: (a') infecting bacteria having a second type of infection mediating structure with phage comprising nucleic acid encoding a library of ligand binders, or a phagemid vector comprising nucleic acid encoding a library of ligand binders and a helper phage, wherein the ⁇ ⁇ t to in o in o in in in
  • step (c) can infect the bacteria with nucleic acid encoding the ligand binder
  • helper phage using a helper phage to infect the bacteria, wherein the helper phage is restricted so that the phage particles produced by the bacteria are substantially incapable of infecting bacteria having a second type of infection mediating structure but are capable of infecting bacteria having the first or a further type of infection medaiting complex;
  • step (h) adding bacteria having the second type of infection mediating structure so that the infective phage particles produced in step (c) can infect the bacteria with nucleic acid encoding the ligand binder;
  • steps (c) , (d) and (e) can be varied.
  • the method includes the steps of:
  • steps (i) to (h) can be repeated as necessary to obtain one or more ligand binders having the desired specificity.
  • the present invention provides phage and/or phage bound to an infection mediating complex for use in the above method.
  • Figures 1 and 2 show schematically embodiments of the invention employing a phagemid vector system and using N- and F-pili expressing bacteria and M13K07 and IKe as helper phages (a chimeric variant of M13K07 with the same pili restriction as IKe phage) .
  • Figure 3 shows schematically an embodiment of the invention employing a phage vector system to select antibodies capable of binding to an antigen.
  • Figure 4 shows an inhibition assay using approximately 1 x 10 3 IKe phage to infect N-pili bearing cells.
  • phage A number of different types of phage are known having different specificities for infecting target bacteria.
  • the phage generally utilize surface structures on bacteria known as pili, which are used by the bacteria, e.g. for specific binding of macromolecules and for uptake of foreign DNA, to enter the target bacterium in order to complete their life cycles.
  • pili Different types of pili have been recognized on gram-negative bacteria (Bradley, 1980) .
  • Long, flexible pili of the F type are utilized by the commonly used filamentous phage of the Ff type (e.g. M13, fd, fl) for target cell binding and subsequent infection.
  • the Ff phage coat protein responsible for this recognition are named p3.
  • Ff p3 has been characterized in detail (Beck and Zink, 1981) and is composed of a polypeptide of 424 amino acid residues synthesized as a preprotein with an 18 residues leader sequence.
  • the p3 protein is structurally organised in three domains, Nl , N2 and CT (carboxy terminal), where the Nl domain has been shown to be involved in penetration of the bacterial membrane and the N2 domain contains the binding surface essential for specific F- pili recognition (Stengele et al . , 1990).
  • a related filamentous phage has a variant of the p3 coat protein that recognizes a shorter, rigid type of pili, called N-pili.
  • This N-pili binding domain is located upstream of the penetration domain, contrary to the N2 domain of fd and completely different (Endemann et al . , 1992).
  • the IKe penetration domain is homologous to the Nl domain of fd phages, as well as the C-terminal regions (coat-anchoring) .
  • Techniques for genetically engineering antibodies are well known in the art and typically involve manipulating nucleic acid encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs) of an antibody.
  • CDRs complementarity determining regions
  • antibody should be construed as covering antibody fragments, derivatives, functional equivalents and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or synthetic. Chimeric molecules comprising an immunoglobulin binding domain, or equivalent, fused to another polypeptide are also included. The cloning and expression of chimeric antibodies are described in EP 0120694A and EP 0125023A.
  • binding fragments are (i) the Fab fragment consisting of VL, VH, CL and CHI domains; (ii) the Fd fragment consisting of the VH and CHI domains; (iii) the Fv fragment consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward et al .
  • the library of potential ligand binders is constructed using techniques well known in the art employing phage or phagemid/helper phage.
  • a phagemid vector can be used to transform bacteria having a second type of infection mediating structure different from the first with a library of candidate ligand binders, e.g. by ligating antibody fragments obtained by PCR amplification of cDNA derived from antibody producing cells into the phagemid vector.
  • a helper phage can then be used which is restricted to infecting bacteria having the second type of infection mediating structure to infect the bacteria transformed with the candidate ligand binders.
  • the helper phage may be so restricted as it is specific for that type of bacteria (e.g. the IKe helper phage is specific for N-pili carrying bacteria) , or is chimeric and has had its infectivity altered (e.g. the M13K07 ch helper phage, engineered to be specific for N-pili carrying bacteria) .
  • the bacteria can be transformed with nucleic acid encoding the library of ligand binders using a phage.
  • a library of phage particles displaying the ligand binder fragments as fusions with the coat protein the phage particles being capable of infecting via the second type of infection mediating structure, but restricted so as to be substantially incapable of infecting via the first type of infection mediating structure.
  • a N-pili restricted phage is used in this step such as an IKe phage or a p3 chimeric helper phage based on M13K07.
  • the phage particles displaying the ligand binders will be unable to infect bacteria displaying F- pili.
  • step (b) the phage particles displaying the ligand binders are exposed to infection mediating complexes comprising a target ligand and a component capable of mediating infection via the first type of infection mediating structure.
  • step (b) more that one type of infection mediating complex can be simultaneously or sequentially exposed to the library of ligand binders displayed on the phage particles.
  • the component is preferably all or a part of a phage coat protein capable of specifically mediating infection of bacteria via the first type of infection mediating structure, e.g.
  • the infection mediating complex can be produced recombinantly, e.g. by being expressed as a fusion.
  • methods for synthetically producing the component capable of mediating infection and/or the target ligand can be used.
  • Techniques for coupling synthetically produced target ligands and components for mediating infection are well known in the art.
  • the synthetic approach allows the construction of infection mediating complexes which are non-peptidyl, e.g. nucleic acid or carbohydrate ligands which can be used to screen phage displayed transcription factors.
  • the synthesis of peptidyl and non-peptidyl ligands is well known in the art, see for example J.M. Stewart and J.D.
  • nucleic acid can optionally also be multiplied in the bacteria to further improve the amplification relative against background. It is also possible to recover or salvage the nucleic acid from the bacteria, e.g. by lysis or use of a helper phage . Techniques and vectors for carrying out these steps are provided in Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al . , 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of nucleic acid into cells and gene expression, and analysis of proteins, are described in detail in Current Protocols in Molecular Biology, Ausubel et al . eds . , John Wiley & Sons, 1992.
  • phage stock can be prepared from the bacteria having the first type of infection mediating structure (e.g. a first type of pili) and containing the nucleic acid encoding the ligand binders selected in the first round of selection by infecting the bacteria with phage or helper phage restricted to that first type of bacteria.
  • the bacteria having the first type of infection mediating structure e.g. a first type of pili
  • containing the nucleic acid encoding the ligand binders selected in the first round of selection by infecting the bacteria with phage or helper phage restricted to that first type of bacteria.
  • a further infection mediating complex comprising a target ligand and component capable of mediating infection other than by the first type of infection mediating structure (e.g. the second type of pili or via another structure) can be used, so that the specific interaction of the ligand binder and ligand causes the phage to become infective towards first or a further type of bacteria. It will be clear that these steps can be repeated as required, taking phage particles restricted so that they are incapable of infecting bacteria, and using an infection mediating complex to make those phage in which the displayed ligand binder binds to ligand of the complex infective towards the bacteria.
  • the bacteria used to provide the selectivity of infection by the complex formed between the phage particles and the infection mediated complex are N- or F-pili bacteria.
  • a library of ligand binders e.g. contained in M13 filamentous phages, cannot significantly infect bacteria that express N-pili and which are devoid of F-pili.
  • phage particles displaying ligand binders e.g.
  • antibodies specific for a certain antigen can be given the ability to infect such N-pili carrying bacteria if they bind to an infection mediating complex comprising a ligand capable of binding the ligand binder and a component capable of mediating infection via N-pili, such as a part of a coat protein that can interact with N- pili, e.g. the N-terminal part of p3 from N-pili restricted phage IKe.
  • N-pili restricted phage for example an IKe phage or a p3 chimeric helper phage based on M13K07.
  • a chimeric helper phage can be constructed by replacing the F-pili binding domain of M13 p3 with the N- pili binding domain from phage IKe p3.
  • N-pili bacteria are transformed with a library of antibody fragments as ligands, obtained by ligation of PCR amplified cDNA derived from antibody producing cells or another convenient source into a phagemid vector.
  • the N-pili bacteria are infected with the M13 based p3 chimeric helper phage stock.
  • An F-pili binding p3 -ligand fusion protein (infection mediating complex) is constructed, composed of
  • M13, Nl and N2 domains linked to a polypeptide or glycoprotein antigen are linked to a polypeptide or glycoprotein antigen.
  • the fusion protein is mixed with phage originating from the transformed N-pili bacteria, and hence displaying the antibody library, and with F-pili bacteria.
  • F. F-pili bacteria that have been infected with chimeric phage are selected for by a selection marker (e.g. ampicillin resistance) on the plasmid used.
  • a selection marker e.g. ampicillin resistance
  • a phage stock is prepared from the selected F-pili bacteria, using a F-pili dependent helper phage (e.g. M13K07) .
  • This phage stock contains phage with the genetic information for the selected antibodies and displays the antibodies at their surfaces.
  • N-pili binding p3 -ligand fusion protein is constructed, composed of the N-terminal domain of IKe phage p3 linked to the polypeptide or glycoprotein antigen.
  • the N-pili binding fusion protein is mixed with phage originating from the infected F-pili bacteria, and with N-pili bacteria.
  • J. N-pili bacteria that have been infected with chimeric phage are selected for by a selection marker on the plasmid used.
  • K. A phage stock is prepared from the selected N-pili bacteria, using a N-pili dependent helper phage (e.g. M13K07 ch) . This phage stock contains phage with the genetic information for the selected antibodies and displays the antibodies at their surfaces.
  • Steps D-K are optionally repeated in order to further enrich phage carrying the ligand binders, i.e. antibodies, of interest.
  • the plasmids harbouring the genetic information encoding these antibodies are salvaged.
  • the coding sequence can be then be sequenced to determine the primary structure of the selected antibodies, and/or used for expression of the selected antibodies .
  • figure 1 shows an example using a phagemid system for selecting antibodies that bind to an antigen.
  • N-pili carrying bacteria are transformed with phagemid vectors comprising nucleic acid encoding a library of ligand binders and a chimeric helper phage
  • the phages are mixed with an infection mediating complex comprising one or more antigens (target ligands) fused to p3 of M13.
  • an infection mediating complex comprising one or more antigens (target ligands) fused to p3 of M13.
  • the embodiment of the invention shown in figure 2 differs from that in figure 1 in that in the first round of infection an IKe helper phage is used instead of the M13K07 chimeric helper phage.
  • Figure 3 shows an embodiment employing a phage vector to produce the library of phage particles displaying the antibodies, as opposed to the phagemid vector and helper phage systems shown in figures 1 and 2.
  • This system differs from the helper phage embodiments shown in figures 1 and 2 in that each round of selection employs the bacteria displaying the same type of infection mediating structure (N-pili) .
  • IKe p3-fusion protein The ability of an IKe p3 -fusion protein to mediate infection of F-pili restricted R408 phage displaying antibody fragments into N-pili expressing E. coli was investigated.
  • the fusion protein, LIKebAD2, containing IKe p3 receptor and penetration domain and the AD2 peptide (from cytomegalovirus) was constructed.
  • two complementary oligonucleotides were used containing a 5'KpnI site and a 3 'EcoRI site with the sequence 5'- CCCCGGTACCGCCAACGAGACTATCTACAACACTACCCTCAAGTATGGAGATTGAAT TCCCCC-3'.
  • the two oligonucleotides were allowed to hybridize, digested with Kpnl and EcoRI, gelpurified and subsequently ligated into Kpnl- and EcoRI-digested pUC19 expression vector, resulting in the intermediate vector pAD2.
  • the LIKep3b fragment comprising the genetic information for the receptor and penetration domain of IKe p3 was isolated from PCR-amplified dsIKe phage DNA using the primers :
  • LIKe5' (Hindlll) : 5' -CCAAGCTTCAGCTAAGGCGTAATTATGAAAAGAAAAATAATAGCA-3' and LIKeb3' ( Kpnl ) : 5' -ATCTTCCTTTGTCAGTGAGGTACCAGTTGATC-3' .
  • the fragment was digested with Kpnl and Hindlll, gelpurified and ligated into Kpnl- and Hindlll -digested pAD2 vector, resulting in the expression vector pLIKebAD2.
  • the pLIKebAD2 vector was transformed into E. coli cells and the transformed cells expressed the fusion protein after induction with IPTG.
  • the expressed protein was verified on Western blot using anti-AD2 antibodies.
  • the fusion protein was purified by ion exchange chromatography and the concentration determined by competitive ELISA to be lxlO "5 M.
  • the fusion protein was also shown to inhibit IKe phage infection of N-pili expressing cells in a dose-dependent manner (figure 4) .
  • the fusion protein did not inhibit infection of M13 phage of F-pili expressing bacteria, and a corresponding fusion protein comprising the AD2 epitope and the Nl and N2 domains of M13 p3 did not inhibit infection of IKe phage into N-pili expressing bacteria.
  • LIKebAD2 fusion protein antigen specific selection was performed from a human scFv R408 phage display library (2xl0 9 members) having ampicillin as a selection marker. 10 ⁇ l LIKebAD2 fusion protein diluted to 2xl0 "7 M was mixed with an equal volume of phage stock (10 13 cf ⁇ /ml) and incubated overnight at +4°C. A negative control was made using PBS instead of fusion protein.
  • the cells were used for preparation of phagemide DNA, which was then electroporated into electrocompetent ToplOF' E. coli cells.
  • the transformed cells were grown to log phase in selective medium and infected with R408 helper phages, induced with IPTG and grown for 16 h at 25°C.
  • the phage containing supernatant was PEG-precipitated, redissolved in 100 ⁇ l of PBS, and the titer determined.
  • the phage stock from the first selection with LIKebAD2 was used for a second round of selection, using the same parameters as for the first selection. Phage stocks were made from selected positive and negative bacterial clones, and analysed on antigen-specific ELISA.
  • the OD value obtained for the specific clone was similar to that generated by a control phage (pI3) displaying antibodies with a known specificity for the AD2 epitope of cytomegalovirus .
  • Table 1 AD2 specificity of selected phage as determined by ELISA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des matériels et des méthodes de sélection de liants de ligands présentant des phages capables de se lier spécifiquement à un ligand cible, lesquels utilisent l'infectivité du phage vis-à-vis de différents types de bactéries. Dans cette méthode, une banque de liants de ligands est présentée à la surface de particules de phage, le phage étant restreint pour ne pas infecter des bactéries d'un premier type de structure induisant une infection, mais capable d'infecter des bactéries d'un second type de structure induisant une infection. On met le phage en contact avec un complexe induisant une infection et comprenant un ligand cible et un composant capable d'induire une infection via le premier type de structure induisant une infection, de sorte que la liaison spécifique d'un liant de ligand présenté sur le phage et le ligand cible rendent le phage infectant vis-à-vis des bactéries du premier type de structure induisant une infection.
PCT/GB1998/002371 1997-08-08 1998-08-06 Materiel et methodes de selection de liants de ligands presentant un phage WO1999007842A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU86404/98A AU8640498A (en) 1997-08-08 1998-08-06 Materials and methods for selecting phage displaying ligand binders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9716900.7A GB9716900D0 (en) 1997-08-08 1997-08-08 Method for selecting phage displaying ligand binders
GB9716900.7 1997-08-08

Publications (1)

Publication Number Publication Date
WO1999007842A1 true WO1999007842A1 (fr) 1999-02-18

Family

ID=10817260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/002371 WO1999007842A1 (fr) 1997-08-08 1998-08-06 Materiel et methodes de selection de liants de ligands presentant un phage

Country Status (3)

Country Link
AU (1) AU8640498A (fr)
GB (1) GB9716900D0 (fr)
WO (1) WO1999007842A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013104901A2 (fr) 2012-01-09 2013-07-18 Smith, Stephen E. Nouvelles thérapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614989A1 (fr) * 1993-02-17 1994-09-14 MorphoSys AG Procédé de sélection in vivo des protéines attachées des ligands
WO1995016027A1 (fr) * 1993-12-06 1995-06-15 Bioinvent International Ab Procede de selection de bacteriophages specifiques
WO1996022393A1 (fr) * 1995-01-17 1996-07-25 Bioinvent International Ab Procede perfectionne de selection de bacteriophages specifiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614989A1 (fr) * 1993-02-17 1994-09-14 MorphoSys AG Procédé de sélection in vivo des protéines attachées des ligands
WO1995016027A1 (fr) * 1993-12-06 1995-06-15 Bioinvent International Ab Procede de selection de bacteriophages specifiques
WO1996022393A1 (fr) * 1995-01-17 1996-07-25 Bioinvent International Ab Procede perfectionne de selection de bacteriophages specifiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DUENAS, MARTA ET AL: "Clonal selection and amplification of phage displayed antibodies by linking antigen recognition and phage replication", BIO/TECHNOLOGY (1994), 12(10), 999-1002 CODEN: BTCHDA;ISSN: 0733-222X, XP000575847 *
HOLLIGER, PHILIPP ET AL: "A conserved infection pathway for filamentous bacteriophages is suggested by the structure of the membrane penetration domain of the minor coat protein g3p from phage fd", STRUCTURE (LONDON) (1997), 5(2), 265-275 CODEN: STRUE6;ISSN: 0969-2126, XP002089629 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013104901A2 (fr) 2012-01-09 2013-07-18 Smith, Stephen E. Nouvelles thérapies

Also Published As

Publication number Publication date
GB9716900D0 (en) 1997-10-15
AU8640498A (en) 1999-03-01

Similar Documents

Publication Publication Date Title
Szardenings Phage display of random peptide libraries: applications, limits, and potential
Krebber et al. Selectively-infective phage (SIP): a mechanistic dissection of a novel in vivo selection for protein-ligand interactions
Baek et al. An improved helper phage system for efficient isolation of specific antibody molecules in phage display
US5844076A (en) Totally synthetic affinity reagents
US7049135B2 (en) Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
JP3507073B2 (ja) 特異的結合対の成員の製造方法
JP4312403B2 (ja) （ポリ）ペプチド／タンパク質を、ジスルフィド結合を介してバクテリオファージ粒子に表示させる新規方法
AU2008290537B2 (en) pVII phage display
Zacchi et al. Selecting open reading frames from DNA
WO1997032017A1 (fr) Nouvelle methode pour l'identification de sequences d'acides nucleiques codant pour deux (poly)peptides interactifs, ou plus
KR100961392B1 (ko) 항체 파지 표면제시 라이브러리 제조방법, 상기 방법에의해 제조된 항체 파지 표면제시 라이브러리, 상기 항체파지 표면제시 라이브러리 유전자를 포함한 파지미드 벡터
US8969253B2 (en) Method for screening phage display libraries against each other
Zoller New molecular biology methods for protein engineering
Kwaśnikowski et al. Multivalent display system on filamentous bacteriophage pVII minor coat protein
McConnell et al. Construction and screening of M13 phage libraries displaying long random peptides
AU2003253193B2 (en) Novel tricistronic vectors and uses therefor
Mersich et al. Generation of bioactive peptides by biological libraries
WO1999007842A1 (fr) Materiel et methodes de selection de liants de ligands presentant un phage
Barbas et al. Filamentous phage display
US20050181494A1 (en) Novel lambda phage display system and the process
US20050130124A1 (en) Phagemid display system
McGregor et al. External surface display of proteins linked to DNA-binding domains
Hung et al. Phage Display for Imaging Agent Development
Cebe et al. Size of the ligand complex between the N-terminal domain of the gene III coat protein and the non-infectious phage strongly influences the usefulness of in vitro selective infective phage technology
Rice Development and optimization of bacterial display methodologies for peptide library screening

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA